Indian Vaccine Market To Be Worth Rs 252 Billion By 2025: Jitendra Singh

Union Minister Jitendra Singh said on Sunday that the Indian vaccine market is expected to reach Rs 252 billion by 2025, highlighting the country's progress in the pharmaceutical and biotechnology sectors. On Sunday, Singh, who is leading a...

Bionomics completes enrollment in the phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder

Bionomics Limited, a clinical-stage biopharmaceutical company, announced that it has reached its target enrollment of approximately 200 participants in its multi-center phase 2b ATTUNE clinical trial evaluating BNC210 in Post-Traumatic Stress...

WHO Announces New Pandemic Preparedness Initiative

WHO has launched a new project to assist countries in better preparing for future pandemics. The initiative gives guidelines on integrated planning for reacting to any respiratory infection, such as influenza or coronaviruses...

Why India is a Hotspot for Biotech Startups?

India has a large pool of scientists and engineers and a strong base for research and development,giving biotech startups access to experienced talent.

How Biotech is Revolutionizing the Fight Against Cancer

Cancer has long been a major health concern for people around the world. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for nearly 10 million deaths in 2020 alone.

India's Glenmark Life Sciences says Q4 profit soars 48 per cent on API boost

Glenmark Life Sciences Ltd in India reported a 48% increase in fourth-quarter profit on Thursday, owing to growth in its mainstay business of producing active pharmaceutical ingredients (API) for drugs. The Mumbai-based pharmaceutical company's....

PureTech's Vedanta Biosciences Declares $106.5 mn financing to advance pipeline of defined bacterial consortia therapies

Vedanta Biosciences, a clinical-stage company developing a potential new class of oral therapies based on defined bacterial consortia, announced a $106.5 million funding round to support pivotal-stage development of its lead candidate, VE303,...

Alentis Therapeutics Declares positive results from phase 1 multiple-ascending dose cohorts study

Alentis Therapeutics (Alentis), a clinical-stage biotechnology company developing novel treatments for organ fibrosis and CLDN1+ tumours, announced results from its first-in-human phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1)....

WHO Urges Increased Use Of Recommended Malaria-Fighting Tools

The World Health Organisation (WHO) has issued a call for increased implementation of new and existing malaria interventions to save lives on World Malaria Day.Thanks to an ongoing pilot programme coordinated by WHO, nearly 1.5 million children...

© 2025 India Pharma Outlook. All Rights Reserved.